HilleVax Past Earnings Performance
Past criteria checks 0/6
HilleVax's earnings have been declining at an average annual rate of -23.3%, while the Biotechs industry saw earnings growing at 19.3% annually.
Key information
-23.3%
Earnings growth rate
17.4%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | n/a |
| Return on equity | -81.6% |
| Net Margin | n/a |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
No updates
Revenue & Expenses Breakdown
How HilleVax makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 0 | -150 | 30 | 106 |
| 30 Jun 24 | 0 | -156 | 30 | 113 |
| 31 Mar 24 | 0 | -144 | 29 | 109 |
| 31 Dec 23 | 0 | -124 | 27 | 107 |
| 30 Sep 23 | 0 | -108 | 25 | 91 |
| 30 Jun 23 | 0 | -93 | 23 | 77 |
| 31 Mar 23 | 0 | -119 | 20 | 63 |
| 31 Dec 22 | 0 | -160 | 17 | 46 |
| 30 Sep 22 | 0 | -176 | 14 | 37 |
| 30 Jun 22 | 0 | -221 | 10 | 24 |
| 31 Mar 22 | 0 | -169 | 7 | 16 |
| 31 Dec 21 | 0 | -102 | 6 | 10 |
| 30 Sep 21 | 0 | -66 | 4 | 2 |
| 31 Dec 20 | 0 | -2 | 1 | 0 |
Quality Earnings: HLVX is currently unprofitable.
Growing Profit Margin: HLVX is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: HLVX is unprofitable, and losses have increased over the past 5 years at a rate of 23.3% per year.
Accelerating Growth: Unable to compare HLVX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: HLVX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: HLVX has a negative Return on Equity (-81.55%), as it is currently unprofitable.